Sanara Medtech Inc
NASDAQ:SMTI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26.86
41.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Sanara Medtech Inc
Sanara Medtech Inc
Gross Profit
Sanara Medtech Inc
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sanara Medtech Inc
NASDAQ:SMTI
|
Gross Profit
$70.4m
|
CAGR 3-Years
52%
|
CAGR 5-Years
56%
|
CAGR 10-Years
46%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Gross Profit
$735.3m
|
CAGR 3-Years
19%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Gross Profit
$769.1m
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
18%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Gross Profit
$2.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
11%
|
CAGR 10-Years
17%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Gross Profit
$969.6m
|
CAGR 3-Years
78%
|
CAGR 5-Years
41%
|
CAGR 10-Years
25%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Gross Profit
$620.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
Sanara Medtech Inc
Glance View
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 63 full-time employees. The Company’s products include surgical wound care products, which includes CellerateRX Surgical Activated Collagen (Powder and Gel), and chronic wound care products, which include HYCOL Hydrolyzed Collagen (Powder and Gel), BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel. The surgical wound care products are used in specialties including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, oncology, plastic/reconstructive, podiatric, urology and vascular. The chronic wound care products are used across the post-acute continuum of care, including home health, hospice, physician offices, podiatrists, retail, skilled nursing facilities, and wound care centers.
See Also
What is Sanara Medtech Inc's Gross Profit?
Gross Profit
70.4m
USD
Based on the financial report for Sep 30, 2024, Sanara Medtech Inc's Gross Profit amounts to 70.4m USD.
What is Sanara Medtech Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
46%
Over the last year, the Gross Profit growth was 30%. The average annual Gross Profit growth rates for Sanara Medtech Inc have been 52% over the past three years , 56% over the past five years , and 46% over the past ten years .
You don't have any saved screeners yet
